RayzeBio develops novel peptide mimetic binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter.

Register for Details

For more details on financing and valuation for RayzeBio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about RayzeBio

Forge green plus iconForge green minus icon

What is RayzeBio's funding to date?

RayzeBio has raised $397.75MM to date.
Forge green plus iconForge green minus icon

When was RayzeBio founded?

RayzeBio was founded in 2020.

Who are RayzeBio's major investors?

Perceptive Advisors
Sands Capital Ventures
OrbiMed Advisors
Versant Ventures
Redmile Group
Ally Bridge Group
Samsara Biocapital
Sofinnova Investments
Soleus Capital
Vivo Capital

RayzeBio Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
9/13/2022 Series D $159.75MM raised $XXX.XX $XXX.XX
6/15/2021 Series C $99.63MM raised $XXX.XX $XXX.XX
12/8/2020 Series B $96.86MM raised $XXX.XX $XXX.XX
10/14/2020 Series A $41.51MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.